RAREUltragenyx Pharmaceutical Inc.
$15.49-45% 1Y
$15.49
$12.9052 weeks$36.54
The financials
Ultragenyx Pharmaceutical Inc. by the numbers
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $214M in Q2 2026 (quarter ended Jun 30, 2026), up 28% from the same quarter a year earlier. That came with net loss of $92M. For the full year FY2025, revenue was $673M (+20% year on year) and net income −$575M. Its largest region in Q2 2026 was North America at $121M, 68% of the disclosed total, well ahead of Latin America at 28%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $214M | $167M | +28% |
| Operating income | −$75M | −$108M | n/a |
| Net income | −$92M | −$115M | n/a |
| Diluted EPS | −$0.90 | −$1.17 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| North America | $121M | 68% |
| Latin America | $51M | 28% |
| Asia Pacific | $7.0M | 3.9% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $179.0M (+70%)
Asia Pacific grew +75% year on yearNorth America +17% year on year
Segment Latestquarter on quarteryear on year
- North America$121.0M$121.0Mquarter on quarter +105%year on year +17%+105%+17%
- Latin America$51.0M$51.0Mquarter on quarter +21%year on year +55%+21%+55%
- Asia Pacific$7.0M$7.0Mquarter on quarter +75%year on year +75%+75%+75%
On our screens:Most shorted stocks